Predicting and preventing the cardiotoxicity of cancer therapy

References

• US National Center for Health Statistics, National Vital Statistics Reports, Vol. 54, No. 19, 28 June 2006.
   Google Scholar
• Oeffinger KC, Mertens AC, Sklar CA et al. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med.355, 1572–1582 (2006).
   PubMed Web of Science ®Google Scholar
• Ewer MS and Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol.23, 2900–2902 (2005).
   PubMed Web of Science ®Google Scholar
• Tan C, Tasaka H, Dou-Ping Y et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease: clinical evaluation with special reference to childhood leukemia. Cancer20, 333–353 (1967).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Colan SD, Gelber RD et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med.324, 808–815 (1991).
   PubMed Web of Science ®Google Scholar
• Elliot P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin. Oncol.33, S2–S7 (2006).
   PubMedGoogle Scholar
• Chen B, Peng X et al. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc. Toxicol.7(2), 114–121 (2007).
   PubMed Web of Science ®Google Scholar
• Vasquez-Vivar J, Martasek P, Hogg N et al. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry36, 11293–11297 (1997).
   PubMed Web of Science ®Google Scholar
• Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J. Clin. Invest.65, 128–135 (1980).
   PubMed Web of Science ®Google Scholar
• Kotamraju S, Konorev EA, Joseph J et al. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. J. Biol. Chem.43, 33585–33592 (2000).
   Google Scholar
• Sawyer DB, Fukazawa R, Arstall MA et al. Daunorubicin-induced apoptosis in rat cardiac myocytes in inhibited by dexrazoxane. Circ. Res.84, 257–265 (1999).
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polmorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation112, 3754–3762 (2005).
   PubMed Web of Science ®Google Scholar
• Van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. 2005, Issue 1.
   Google Scholar
• Minotti G, Sarvazyan N. The anthracyclines: when good things go bad. Cardiovasc. Toxicol.7, 53–55 (2007).
   PubMed Web of Science ®Google Scholar
• Steinberg JS, Cohen AJ, Wasserman AG et al. Acute arrhythmogenicity of doxorubicin administration. Cancer60, 1213–1218 (1987).
   PubMed Web of Science ®Google Scholar
• Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am. Heart J.102, 709–718 (1981).
   PubMed Web of Science ®Google Scholar
• Bristow MR, Mason JW, Billingham ME, Daniels Jr. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann. Intern. Med.88, 168–175 (1978).
   PubMed Web of Science ®Google Scholar
• Herman EH, Zhang J, Lipshultz SE et al. Correlation between serum levels of cardiac troponin-T and the severity of chronic cardiomyopathy induced by doxorubicin. J. Clin. Oncol.17, 2237–2243 (1999).
   PubMed Web of Science ®Google Scholar
• Weesner KM, Bledso M, Chauvenet A, Wofford M. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer68(2), 435–438 (1991).
   PubMed Web of Science ®Google Scholar
• Wassmuth R, Lentzsch S, Erdbruegger U et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging – a pilot study. Am. Heart J.141(6), 1007–1013 (2001).
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med.91, 710–717 (1979).
   PubMed Web of Science ®Google Scholar
• Gennari A, Salvadori B, Donati S et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J. Clin. Oncol.17(11), 3596–602 (1999).
   PubMed Web of Science ®Google Scholar
• Al-Shabanah OA, El-Kashef HA, Badary OA, Al-Bekairi AM, Elmazar MM. Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. Pharmacol. Res.41(1), 31–37 (2000).
   PubMedGoogle Scholar
• Sorensen K, Levitt GA, Bull C et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer97(8), 1991–1998 (2003).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Sallan SE et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J. Clin. Oncol.20(23), 4517–4522 (2002).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Orav EJ, Sanders SP et al. Limitations of fractional shortening as an index of contractility in pediatric patients infected with HEV. J. Pediatr.125, 563–570 (1994).
   PubMedGoogle Scholar
• Giantris A, Abdurrahman L, Hinkle A et al. Anthracycline-induced cardiotoxicity in children and young adults. Crit. Rev. Oncol. Hematol.27, 53–68 (1998).
   PubMed Web of Science ®Google Scholar
• Kapusta L, Thijssen JM, Groot-Loonen J et al. Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med. Biol.26, 1099–1108 (2000).
   PubMed Web of Science ®Google Scholar
• Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat. Rep.62, 857–864 (1978).
   PubMedGoogle Scholar
• Billingham ME, Mason JW, Bristow MR et al. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep.62, 865–872 (1978).
   PubMedGoogle Scholar
• Suzuki T, Hayakhi D et al. Elevated B-type natriuretic peptide levels after anthracyclin administration. Am. Heart J.136, 362–363 (1998).
   PubMed Web of Science ®Google Scholar
• Okumura H, Iuchi K et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haemetologica104, 158–163 (2000).
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R, L’Ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr. Blood Cancer49, 812–816 (2007).
   PubMed Web of Science ®Google Scholar
• Herman EH, Zhang J et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J. Clin. Oncol.17, 2237–2243 (1999).
   PubMed Web of Science ®Google Scholar
• Postma A, Bink-Boelkens MT, Beaufort-Krol Gc et al. Late cardiotoxicity after treatment for a malignant bone tumor. Med. Pediatr. Oncol.26, 240–237 (1996).
   Google Scholar
• Schwartz RG, McKenzie WB, Alexander J et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven year experience using serial radionuclide angiocardiography. Am. J. Med.82, 1109–1118 (1987).
   PubMed Web of Science ®Google Scholar
• van Dalen EC, van den Berg M, Caron HN, Kremer LCM. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur. J. Cancer42, 3199–3205 (2006).
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Rayson D, Vincent M et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res. Treat.107, 443–450 (2008).
   PubMedGoogle Scholar
• Harris L, Batist G, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multi-center trial as first-line therapy of metastatic breast carcinoma. Cancer24, 25–36 (2002).
   Google Scholar
• van Dalen EC, van der Pal JHJ, Caron HN, Kremer LCM. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst. Rev. 2006, Issue 4. Art. No.: CD005008. DOI: 10.1002/14651858.CD005008.pub2.
   Google Scholar
• Lahtinen R, Kuikka J, Nousiainen T et al. Cardiotoxicity of epirubicin and doxorubicin: A double-blind randomized study. Eur. J. Haemotol.46, 301–305 (1991).
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Scott LJ. Dexrazoxane. A review of its use for cardioprotection during anthracycline chemotherapy. Drugs65, 1005–1024 (2005).
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Gerber MC et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol.15(4), 1318–1332 (1997).
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med.351, 145–153 (2004).
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J. Am. Coll. Cardiol.36, 517–522 (2000).
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation114, 2474–2481 (2006).
   PubMed Web of Science ®Google Scholar
• Santos DL, Moreno AJ, Leino RL et al. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol. Appl. Pharmacol.185, 218–227 (2002).
   PubMed Web of Science ®Google Scholar
• Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol.48, 2258–2262 (2006).
   PubMed Web of Science ®Google Scholar
• Tallaj JA, Franco V, Rayburn BK et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J. Cardiac Fail.9(5), S86 (2003).
   Google Scholar
• ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. J. Am. Coll. Cardiol.46, 1116–1143 (2005).
   Web of Science ®Google Scholar
• McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: a unique antineioplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med.111, 273–279 (1989).
   PubMed Web of Science ®Google Scholar
• Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol.13, 2688–2699 (1995).
   PubMed Web of Science ®Google Scholar
• Gehl J, Boesgaard M, Paaske T et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann. Oncol.7, 687–693 (1996).
   PubMed Web of Science ®Google Scholar
• Pentassuglia L, Timolati F, Seifriz F, Abudukadier K, Suter TM, Zuppinger C. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp. Cell Res.313(8), 1588–601 (2007).
   PubMed Web of Science ®Google Scholar
• Gianni L, Capri G. Experience at the Instituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer. Semin. Oncol.24, S3-1–S3-3 (1997).
   Google Scholar
• Perotti S, Cresta G, Grasselli G et al. Cardiotoxic effects of anthracycline-taxane combinations. Expert Opin. Drug Saf.2, 59–71 (2003).
   PubMedGoogle Scholar
• Craddock C. Haemopoietic stem-cell transplantation: recent progress and future promise. Lancet Oncol.1, 227–234 (2000).
   PubMedGoogle Scholar
• De Jonge ME, Huitema A, Rodenhuis S, Beijnen J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet.44(11), 1135–1164 (2005).
   PubMed Web of Science ®Google Scholar
• Lee CK, Harman GS, Hohl RJ et al. Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment. Bone Marrow Transplant.18, 573–577 (1996).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Colvin OM, Aisaka K et al. Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res.50, 2455–2462 (1990).
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer7, 332–344 (2007).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol.20, 1215–1221 (2002).
   PubMed Web of Science ®Google Scholar
• Lee KF, Simon H, Chen H et al. Requirement for neuregulin receptor ERBB2 in neural and cardiac development. Nature378, 394–398 (1995).
   PubMed Web of Science ®Google Scholar
• Gassman M, Casagranda F, Orioli D et al. Aberrant neural and cardiac development in mice lacking the ERBB4 neuregulin receptor. Nature378, 390–394 (1995).
   PubMedGoogle Scholar
• Meyer D and Birchmeier C. Multiple essential functions of neuregulin in development. Nature378, 386–390 (1995).
   PubMed Web of Science ®Google Scholar
• Cote GM, Miller TA, LeBrasseur NK et al. Neuregulin-1 α and β isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Exp. Cell Res.311, 135–146 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao YY, Sawyer DB, Baliga RR et al. Neuregulins promote survival and growth of cardiac myocytes. J. Biol. Chem.273, 10261–10269 (1998).
   PubMed Web of Science ®Google Scholar
• Perez EA, Byrne Ja, Hammond IW et al. Results of an analysis of cardiac function in 2812 patients treated with lapatinib. Proc. Am. Soc. Clin. Oncol.24, (Abstr 583) (2006).
   Google Scholar
• Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med.355, 2733–2743 (2006).
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood105, 2640–2653 (2005).
   PubMed Web of Science ®Google Scholar
• Kerkela R, Luanda G, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med.12, 908–916 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen MH, Williams G, Johnson JR et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res.8, 935–942 (2002).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol.23, 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet370, 2011–2019 (2007).
   PubMed Web of Science ®Google Scholar
• Strevel EL, Ing DS, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J. Clin. Oncol.25, 3362–3371 (2007).
   PubMed Web of Science ®Google Scholar
• Desai J, Yassa L, Marqusae E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann. Intern. Med.145, 660–664 (2006).
   PubMed Web of Science ®Google Scholar
• Eskens F, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur. J. Cancer42, 3127–3139 (2006).
   PubMed Web of Science ®Google Scholar
• Shiojima I, Sato K, Izumiya Y et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest.115, 2108–2118 (2005).
   PubMed Web of Science ®Google Scholar
• Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated cardiovascular disease. Crit. Rev. Oncol./Hematol.45, 55–75 (2003).
   PubMed Web of Science ®Google Scholar
• Gyenes G, Rutqvist LE, Liedberg A et al. Long-term cardiac morbidity and mortality in a randomized trial of pre- and post-operative radiation therapy versus surgery alone in primary breast cancer. Radiother. Oncol.48(2), 185–90 (1998).
   PubMed Web of Science ®Google Scholar
• Martin RG, Ruckdeschel J, Chang P et al. Radiation-related pericarditis. Am. J. Cardiol.35, 216–220 (1975).
   PubMed Web of Science ®Google Scholar
• Carlson RG, Mayfield WR, Normann S et al. Radiation-associated valvular disease. Chest99, 538–545 (1991).
   PubMed Web of Science ®Google Scholar
• Hooning MJ, Botma A, Aleman B et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J. Natl Cancer Inst.99, 365–75 (2007).
   PubMedGoogle Scholar
• Miltenyi Z, Keresztes K, Garai I et al. Radiation-induced coronary artery disease in Hodgkin’s disease. Cardiovasc. Radiat. Med.5, 38–43 (2004).
   PubMedGoogle Scholar
• McEniery PT, Dorosti K, Schiavone WA et al. Clinical and angiographic features of coronary artery disease after chest irradiation. Am. J. Cardiol.60, 1020–1024 (1987).
   PubMed Web of Science ®Google Scholar
• Senkus-Konefka E, Jassem J. Cardiovascular effects of breast cancer radiotherapy. Cancer Treat. Rev.33, 578–593 (2007).
   PubMed Web of Science ®Google Scholar